Similarly, the mutational profile of the R0 cohort did not substantially differ from the overall TCGA study population, where, apart the prevalent p53 mutation, few other genes were commonly mutated and in a small fraction of patients, thus confirming the high mutational heterogeneity of this tumor type. This evidence concerns the gene TP53 and neoplasm.